
Colorectal cancer is the third most commonly diagnosed cancer worldwide, with incidence rising in younger age groups in high-income countries. Surgery remains the cornerstone of curative-intent treatment, complemented by chemotherapy, targeted agents, and immunotherapy, particularly in microsatellite instability-high tumours. Liquid biopsy for minimal residual disease detection and early detection programmes are rapidly advancing.
